Neuren Pharmaceuticals

About:

Neuren Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of brain injuries and neurodegeneration.

Website: http://www.neurenpharma.com

Description:

Neuren Pharmaceuticals Limited is a biopharmaceutical company developing drugs for brain injury and neurodegeneration. The drugs target acute indications of brain injury such as traumatic brain injury, as well as chronic conditions such as Parkinson’s and Alzheimer’s diseases. Neuren is also engaged in research and development in metabolic disorders such as cancers related to the functions of growth hormone. Neuren has three lead candidates; Motiva™ and NNZ-2566 presently in clinical development to treat three different neurological conditions, and NNZ-2591 in preclinical development for Parkinson’s disease dementia and other chronic neurodegenerative conditions. Neuren has operations in New Zealand (Auckland based head office), Australia and the United States, and is listed on the Australian Securities Exchange (ASX: NEU).

Total Funding Amount:

$21.5M

Estimated Revenue Range:

$100M to $500M

Headquarters Location:

Camberwell South, Victoria, Australia

Founded Date:

2004-01-01

Contact Email:

enquiries(AT)neurenpharma.com

Founders:

Number of Employees:

11-50

Last Funding Date:

2013-10-21

IPO Status:

Public

Industries:

© 2025 bioDAO.ai